Hormonal and chemotherapeutic systemic therapy for metastatic prostate cancer

R. Panvichian, K. J. Pienta

Research output: Contribution to journalReview articlepeer-review

Abstract

Background: Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in men in the United States. It is estimated that over 300,000 men will have been diagnosed with prostate cancer in 1996, and more than 40,000 will have died of this disease. Methods: The authors combined their experience with a review of the literature on management of this disease to examine the effectiveness of treatments for both localized and metastatic prostate cancer. Results: Surgery and radiation therapy are potentially curative modalities for cancer still limited to the gland. Androgen ablation therapy results in stabilization or regression of metastatic disease in most instances but is not curative. Some new approaches are described for patients with hormone-refractory prostate cancer. Conclusions: Newer tumor-biology-based combinations are promising in the treatment of hormone-refractory prostate cancer, but their effect on patient survival needs to be evaluated in larger clinical trials.

Original languageEnglish (US)
Pages (from-to)493-500
Number of pages8
JournalCancer Control
Volume3
Issue number6
DOIs
StatePublished - 1996

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Hormonal and chemotherapeutic systemic therapy for metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this